LP
DNTH icon

Longaeva Partners’s Dianthus Therapeutics DNTH Stock Holding History

Longaeva Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$984K – 134
2025
Q3 		$984K Buy
+25,000
New +$639K 0.14% 62

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Longaeva Partners's DNTH Position: Q4 2025 in Review

Longaeva Partners sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 25,000 shares — an estimated $984K sold.

Longaeva Partners first reported a position in DNTH in Q3 2025 and held it in 1 quarter. The position peaked at $984K in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Longaeva Partners reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Longaeva Partners sold 25,000 Dianthus Therapeutics shares in Q4 2025, an estimated $984K.
  • Longaeva Partners first reported a position in Dianthus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Longaeva Partners's Dianthus Therapeutics position peaked at $984K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Longaeva Partners's 13F filing for Q4 2025, filed 17 Feb 2026.